Tag Archive for: IVD

Brazil and Mexico Lead IVD Investments in Latin America

/0 Comments/by Daniel Granderson
Read more

China: Molecular Point-of-Care’s International Market to Watch

/by Daniel Granderson

Molecular point-of-care (mPOC) is a multi-billion dollar market with expanding international intrigue. Though the mPOC market is led by North America and Europe, the Asia-Pacific region makes up 10% of the market’s worldwide sales, with China positioned as a burgeoning power within the APAC. Kalorama Information, a leading medical market research firm, covers mPOC’s global […]

Read more

2023 Healthcare Trend: Growth in $21 Billion Molecular Diagnostics Market

/by Daniel Granderson

Future molecular IVD sales buoyed by COVID-19, infectious diseases, and sexually transmitted infections There is a market in excess of $21 billion for molecular testing technologies, reveals medical market research publisher Kalorama Information in The World Market for Molecular Diagnostics Tests, 11th Edition, a recent report added to the firm’s Knowledge Center subscription.  The majority […]

Read more

127.4 Billion-Dollar IVD Market Blooms

/by Bruce Carlson

Abbott Leads, Roche Close Second. COVID -19 Tests Largest Share, But Growth Comes from non-COVID The world in vitro diagnostic (IVD) market will reach $127.4 billion dollars in 2022, according to LabPulse.com’s sister publication Kalorama Information.  That’s the finding from the firm’s market research report, The Worldwide Market for In Vitro Diagnostics, 15th edition.  REPORT: […]

Read more

IVD in India: Growing, Aging Population Impacts Healthcare

/by Daniel Granderson

India, which is expected to surpass China as the most populous country in the world by 2023, has a growing $1,482 million ($1.5 billion) in vitro diagnostics (IVD) industry that is forecast to increase through 2026, as reported by Kalorama Information in the new medical market research study, In Vitro Diagnostics (IVD) in India. The […]

Read more

106 Billion IVD Procedures and Counting

/by Daniel Granderson

“Medical market researcher Kalorama Information forecasts exponential growth in both in vitro diagnostics (IVD) procedures and sales between 2021 and 2026.”   The global in vitro diagnostics (IVD) procedures market continues to grow off momentum originating at the height of the pandemic and lingering on today. There are currently 106,624 million (106 billion) in vitro […]

Read more

COVID-19 and 6 Other Trends Impacting the In Vitro Diagnostics (IVD) Market

/by Daniel Granderson

  “In many ways, the IVD testing market is center stage for the fight against the coronavirus…The COVID-19 market continues to play a major role in the growth of the IVD market with tests for the virus representing 27% of sales in 2021.” – Kalorama Information   Make no mistake, the in vitro diagnostics (IVD) […]

Read more

Cancer IVD: 4 Trends to Watch in $5.5 Billion Market

/by Daniel Granderson

  Whether affecting the lungs, colorectal system, stomach, liver, breasts, or other parts of the body, few medical maladies carry the inherent gravitas of cancer. Annually, millions of new cancer cases are diagnosed and millions of cancer linked deaths occur worldwide.  Undoubtedly, cancer poses one of the greatest threats to human health globally. This proliferating […]

Read more

POC Testing Joins “War” on COVID-19 with 45-Minute Cepheid Test

/by Bruce Carlson

We projected in Kalorama’s  mPOC market study that molecular point of care ( mPOC ) would lead the fight in meeting the demand for COVID-19 testing with accurate and fast results.   Lab staff is at a premium, hospitals are taxed, and testing needs to happen where it can be useful to isolate patients.  We suggested that […]

Read more

Thermo Fisher set to acquire Qiagen after all in $11.5B deal

/by Bruce Carlson

Courtesy of LabPulse.com March 3, 2020 — After an on-and-off courtship, Thermo Fisher Scientific announced it is set to acquire Qiagen in a deal worth $11.5 billion. The transaction will give Thermo Fisher access to Qiagen’s molecular diagnostics expertise and potentially lead to faster development of diagnostic tests. The deal values Qiagen at 39 euros ($44) per […]

Read more